COVID-19 Associated Rhino-Orbital-Cerebral Mucormycosis: Clinical Features, Antifungal Susceptibility, Management and Outcome in a Tertiary Hospital in Iran
Background Despite the unprecedented surge in the incidence of mucormycosis in the COVID-19 era, the antifungal susceptibility patterns (ASPs) of COVID-19 associated mucormycosis (CAM) isolates have not been investigated so far and it is unclear if the high mortality rate associated with CAM is driven by decreased susceptibility of Mucorales to antifungal drugs. Objectives To describe the clinical, mycological, outcome and in vitro ASPs of CAM cases and their etiologies from Iran. Patients/Methods A prospective study from January 2020 to January 2022 at a referral tertiary hospital in Tehran, Iran was conducted for screening mucormycosis through histopathology and mycological methods. The identity of Mucorales isolates was revealed with ITS-panfungal PCR& sequencing and MALDI-TOF. The AS for amphotericin B, itraconazole, isavuconazole and posaconazole was cleared according to the EUCAST antifungal susceptibility testing protocol. Result A total of 150 individuals were diagnosed with CAM. Males constituted 60.7% of the population. The mean age was 54.9 years. Diabetes was the leading risk factor (74.7%). The median interval between diagnosis of COVID-19 and CAM was 31 days. The recovery rate of culture was as low as 41.3% with Rhizopus arrhizus being identified as the dominant (60; 96.7%) agent. Amphotericin B ($ MIC_{50} $ = 0.5 µg/ml) demonstrated the highest potency against Mucorales. Conclusion Majority of the cases had either diabetes, history of corticosteroid therapy or simultaneously both conditions. Accordingly, close monitoring of blood glucose should be considered. The indications for corticosteroids therapy are recommended to be optimized. Also, an anti Mucorales prophylaxis may be necessitated to be administrated in high risk individuals. Although amphotericin B was the most active agent, a higher rate of resistance to this antifungal was noted here in comparison with earlier studies on mucormycetes from non-CAM cases..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:188 |
|---|---|
| Enthalten in: |
Mycopathologia - 188(2023), 5 vom: 06. Sept., Seite 783-792 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Abdorahimi, Mahsa [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| Themen: |
|---|
| Anmerkungen: |
© The Author(s), under exclusive licence to Springer Nature B.V. 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. |
|---|
| doi: |
10.1007/s11046-023-00785-3 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR053359909 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR053359909 | ||
| 003 | DE-627 | ||
| 005 | 20231011064640.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231011s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s11046-023-00785-3 |2 doi | |
| 035 | |a (DE-627)SPR053359909 | ||
| 035 | |a (SPR)s11046-023-00785-3-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Abdorahimi, Mahsa |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a COVID-19 Associated Rhino-Orbital-Cerebral Mucormycosis: Clinical Features, Antifungal Susceptibility, Management and Outcome in a Tertiary Hospital in Iran |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © The Author(s), under exclusive licence to Springer Nature B.V. 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. | ||
| 520 | |a Background Despite the unprecedented surge in the incidence of mucormycosis in the COVID-19 era, the antifungal susceptibility patterns (ASPs) of COVID-19 associated mucormycosis (CAM) isolates have not been investigated so far and it is unclear if the high mortality rate associated with CAM is driven by decreased susceptibility of Mucorales to antifungal drugs. Objectives To describe the clinical, mycological, outcome and in vitro ASPs of CAM cases and their etiologies from Iran. Patients/Methods A prospective study from January 2020 to January 2022 at a referral tertiary hospital in Tehran, Iran was conducted for screening mucormycosis through histopathology and mycological methods. The identity of Mucorales isolates was revealed with ITS-panfungal PCR& sequencing and MALDI-TOF. The AS for amphotericin B, itraconazole, isavuconazole and posaconazole was cleared according to the EUCAST antifungal susceptibility testing protocol. Result A total of 150 individuals were diagnosed with CAM. Males constituted 60.7% of the population. The mean age was 54.9 years. Diabetes was the leading risk factor (74.7%). The median interval between diagnosis of COVID-19 and CAM was 31 days. The recovery rate of culture was as low as 41.3% with Rhizopus arrhizus being identified as the dominant (60; 96.7%) agent. Amphotericin B ($ MIC_{50} $ = 0.5 µg/ml) demonstrated the highest potency against Mucorales. Conclusion Majority of the cases had either diabetes, history of corticosteroid therapy or simultaneously both conditions. Accordingly, close monitoring of blood glucose should be considered. The indications for corticosteroids therapy are recommended to be optimized. Also, an anti Mucorales prophylaxis may be necessitated to be administrated in high risk individuals. Although amphotericin B was the most active agent, a higher rate of resistance to this antifungal was noted here in comparison with earlier studies on mucormycetes from non-CAM cases. | ||
| 650 | 4 | |a COVID-19 |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Rhino-orbital-cerebral mucormycosis |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Diabetes |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Pakdel, Farzad |4 aut | |
| 700 | 1 | |a Salehi, Mohammadreza |4 aut | |
| 700 | 1 | |a Alcazar-Fuoli, Laura |4 aut | |
| 700 | 1 | |a Hashemi, Seyed Jamal |4 aut | |
| 700 | 1 | |a Daie Ghazvini, Roshanak |4 aut | |
| 700 | 1 | |a Ahmadkhani, Fardin |4 aut | |
| 700 | 1 | |a Ahmadikia, Kazem |4 aut | |
| 700 | 1 | |a Abdollahi, Alireza |4 aut | |
| 700 | 1 | |a Debran, Juan Carlos Soto |4 aut | |
| 700 | 1 | |a Tabari, Azin |4 aut | |
| 700 | 1 | |a Farrokh, Fatemeh |4 aut | |
| 700 | 1 | |a Mousavand, Atefeh |4 aut | |
| 700 | 1 | |a Afarinesh Khaki, Pegah |4 aut | |
| 700 | 1 | |a Salami Khaneshan, Arezoo |4 aut | |
| 700 | 1 | |a Ibrahim, Ashraf S. |4 aut | |
| 700 | 1 | |a Khodavaisy, Sadegh |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Mycopathologia |d Dordrecht [u.a.] : Springer Science + Business Media B.V., 1938 |g 188(2023), 5 vom: 06. Sept., Seite 783-792 |w (DE-627)SPR016057945 |w (DE-600)2003647-4 |x 1573-0832 |7 nnns |
| 773 | 1 | 8 | |g volume:188 |g year:2023 |g number:5 |g day:06 |g month:09 |g pages:783-792 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1007/s11046-023-00785-3 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 951 | |a AR | ||
| 952 | |d 188 |j 2023 |e 5 |b 06 |c 09 |h 783-792 | ||